{
    "organizations": [],
    "uuid": "37df8f057a3405f291b34f0061c978fa71fd1ef1",
    "author": "",
    "url": "https://www.reuters.com/article/brief-fda-approves-xgeva-for-the-prevent/brief-fda-approves-xgeva-for-the-prevention-of-skeletal-related-events-in-patients-with-multiple-myeloma-idUSASB0BZWZ",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Approves XGEVA (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 5, 2018 / 2:08 PM / Updated 8 minutes ago BRIEF-FDA Approves XGEVA (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma Reuters Staff \nJan 5 (Reuters) - Amgen Inc: \n* FDA APPROVES XGEVA® (DENOSUMAB) FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA \n* AMGEN INC - APPROVAL IS BASED ON DATA FROM PIVOTAL PHASE 3 ‘482 STUDY WHICH ENROLLED 1,718 PATIENTS Source text for Eikon: Further company coverage:",
    "published": "2018-01-05T16:07:00.000+02:00",
    "crawled": "2018-01-05T16:22:00.018+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "approves",
        "xgeva",
        "denosumab",
        "prevention",
        "event",
        "patient",
        "multiple",
        "myeloma",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "amgen",
        "inc",
        "fda",
        "approves",
        "denosumab",
        "prevention",
        "event",
        "patient",
        "multiple",
        "myeloma",
        "amgen",
        "inc",
        "approval",
        "based",
        "data",
        "pivotal",
        "phase",
        "study",
        "enrolled",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}